The Onset of IgG4-related Retroperitoneal Fibrosis under Administration of a TNF Inhibitor in a Rheumatoid Arthritis Patient

Intern Med. 2023 Nov 1;62(21):3251-3254. doi: 10.2169/internalmedicine.1326-22. Epub 2023 Mar 15.

Abstract

An 80-year-old woman with rheumatoid arthritis during treatment with etanercept, a tumor necrosis factor (TNF) inhibitor, showed swelling of the salivary glands and retroperitoneal fibrosis, which was diagnosed as IgG4-related disease. Although some reports have shown the efficacy of TNF inhibitors for IgG4-related disease or retroperitoneal fibrosis, TNF inhibitors sometimes cause paradoxical reactions like psoriasis, and the mechanisms are considered to involve the upregulation of plasmacytoid dendritic cells and IFN-α, which is also common in patients with IgG4-related disease. This is a case report of IgG4-related retroperitoneal fibrosis with the possibility of a rare paradoxical reaction by a TNF inhibitor.

Keywords: IgG4 related disease; TNF inhibitor; retroperitoneal fibrosis; rheumatoid arthritis.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Arthritis, Rheumatoid* / drug therapy
  • Female
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G4-Related Disease*
  • Retroperitoneal Fibrosis* / chemically induced
  • Retroperitoneal Fibrosis* / diagnosis
  • Retroperitoneal Fibrosis* / drug therapy
  • Tumor Necrosis Factor Inhibitors

Substances

  • Tumor Necrosis Factor Inhibitors
  • Immunoglobulin G